Mirabegron and Hospitalisation - a phase IV clinical study of FDA data

Summary:

Hospitalisation is reported as a side effect among people who take Mirabegron (mirabegron), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Vitamin B12, and have Parkinson's disease.

The phase IV clinical study analyzes which people have Hospitalisation when taking Mirabegron. It is created by eHealthMe based on reports of 5,378 people who have side effects when taking Mirabegron from the FDA, and is updated regularly.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 5,414 Mirabegron users. Check the latest studies of Mirabegron.

What is Hospitalisation?

Hospitalisation is found to be associated with 1,715 drugs and 1,135 conditions by eHealthMe. Check the latest studies of Hospitalisation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

5,378 people reported to have side effects when taking Mirabegron.
Among them, 41 people (0.76%) have Hospitalisation.

Among these 41 people:

How long have people been on Mirabegron when they have Hospitalisation? *

What is the gender of people who have Hospitalisation when taking Mirabegron? *

female: 70.27 %
male: 29.73 %

What is the age of people who have Hospitalisation when taking Mirabegron? *

What are other drugs people take besides Mirabegron? *

What are other side effects people have besides Hospitalisation? *

Malaise (a feeling of general discomfort or uneasiness): 14 people, 34.15%
Diarrhea: 13 people, 31.71%
Hypotension (abnormally low blood pressure): 11 people, 26.83%
Nausea And Vomiting: 10 people, 24.39%
Pain: 10 people, 24.39%
Weight Decreased: 9 people, 21.95%
Weakness: 9 people, 21.95%
Nausea (feeling of having an urge to vomit): 9 people, 21.95%
Mobility Decreased (ability to move is reduced): 8 people, 19.51%
Tremor (trembling or shaking movements in one or more parts of your body): 8 people, 19.51%

What are the existing conditions these people have? *

Parkinson's Disease: 12 people, 29.27%
Pain: 8 people, 19.51%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 7 people, 17.07%
Nausea (feeling of having an urge to vomit): 6 people, 14.63%
Haemoglobin Decreased: 5 people, 12.20%
Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 5 people, 12.20%
Constipation: 3 people, 7.32%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 7.32%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 2 people, 4.88%
Agitation (state of anxiety or nervous excitement): 2 people, 4.88%

* Approximation only. Some reports may have incomplete information.

Do you take Mirabegron and have Hospitalisation?

- Check whether Hospitalisation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mirabegron:

Mirabegron (5,414 reports)

Hospitalisation treatments and more:

Hospitalisation (143,651 reports)

Browse all side effects of Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hospitalisation:

Hospitalisation (1,715 drugs)

Browse all the conditions that are associated with Hospitalisation:

Hospitalisation (1,135 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mirabegron (the active ingredients of Mirabegron) and Mirabegron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.